Perioperative Serplulimab‑based Chemoimmunotherapy in Stage IV Large Cell Neuroendocrine Carcinoma of the Lung: A Case Report

Overview

Journal Oncol Lett

Specialty Oncology

Date 2024 Sep 25

PMID 39319214

Authors

Shuliang Zhang

Jianting Du

Chuanquan Lin

Maohui Chen

Yizhou Huang

Chun Chen

Bin Zheng

Affiliations

Soon will be listed here.

Abstract

Large cell neuroendocrine carcinoma (LCNEC) is a rare and enigmatic tumor, characterized by neuroendocrine features and a poor prognosis similar to small cell lung cancer (SCLC). The present report details the case of a 45-year-old male with oligometastatic stage IV LCNEC who achieved clinical cure after undergoing perioperative immunochemotherapy. Despite the typical non-recommendation of surgery for stage IV cases, based on the insistence of the patient, the present study initiated three cycles of neoadjuvant therapy combining serplulimab (a programmed cell death protein 1 inhibitor) with chemotherapy, resulting in the radiological disappearance of the tumor. Pathological complete response was confirmed following resection of the primary tumor. The treatment continued with three cycles of adjuvant therapy using serplulimab and chemotherapy, followed by maintenance therapy with serplulimab alone. After 17 cycles of maintenance therapy, a positron emission tomography-computed tomography scan revealed a complete metabolic response of the metastasis, and radiological scans revealed no visible tumor or distant metastasis, indicating a clinical cure. Event-free survival has exceeded 11 months, and overall survival has exceeded 14 months. The present case highlights the efficacy of immunochemotherapy in treating advanced LCNEC.

References

De Pas T, Giovannini M, Manzotti M, Trifiro G, Toffalorio F, Catania C . Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib. J Clin Oncol. 2011; 29(34):e819-22. DOI: 10.1200/JCO.2011.36.2251. View

Steven A, Fisher S, Robinson B . Immunotherapy for lung cancer. Respirology. 2016; 21(5):821-33. DOI: 10.1111/resp.12789. View

Sun L, Cen W, Tang W, Long Y, Yang X, Ji X . Smoking status combined with tumor mutational burden as a prognosis predictor for combination immune checkpoint inhibitor therapy in non-small cell lung cancer. Cancer Med. 2021; 10(19):6610-6617. PMC: 8495280. DOI: 10.1002/cam4.4197. View

Fan Y, Ma K, Wang C, Ning J, Hu Y, Dong D . Prognostic value of PD-L1 and PD-1 expression in pulmonary neuroendocrine tumors. Onco Targets Ther. 2016; 9:6075-6082. PMC: 5063491. DOI: 10.2147/OTT.S115054. View

Chauhan A, Arnold S, Kolesar J, Thomas H, Evers M, Anthony L . Immune checkpoint inhibitors in large cell neuroendocrine carcinoma: current status. Oncotarget. 2018; 9(18):14738-14740. PMC: 5865703. DOI: 10.18632/oncotarget.24553. View

Hellmann M, Ciuleanu T, Pluzanski A, Lee J, Otterson G, Audigier-Valette C . Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. N Engl J Med. 2018; 378(22):2093-2104. PMC: 7193684. DOI: 10.1056/NEJMoa1801946. View

Shah M, Goldner W, Benson A, Bergsland E, Blaszkowsky L, Brock P . Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021; 19(7):839-868. DOI: 10.6004/jnccn.2021.0032. View

Sun J, Ahn M, Ahn J, Um S, Kim H, Kim H . Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer?. Lung Cancer. 2012; 77(2):365-70. DOI: 10.1016/j.lungcan.2012.04.009. View

Zhang X, Sun Y, Miao Y, Xu S . Immune Checkpoint Inhibitor Therapy Achieved Complete Response for Drug-Sensitive Mutation-Negative Metastatic Pulmonary Large-Cell Neuroendocrine Carcinoma with High Tumor Mutation Burden: A Case Report. Onco Targets Ther. 2020; 13:8245-8250. PMC: 7443410. DOI: 10.2147/OTT.S259893. View

10.

Tsuruoka K, Horinouchi H, Goto Y, Kanda S, Fujiwara Y, Nokihara H . PD-L1 expression in neuroendocrine tumors of the lung. Lung Cancer. 2017; 108:115-120. DOI: 10.1016/j.lungcan.2017.03.006. View

11.

Iyoda A, Hiroshima K, Moriya Y, Iwadate Y, Takiguchi Y, Uno T . Postoperative recurrence and the role of adjuvant chemotherapy in patients with pulmonary large-cell neuroendocrine carcinoma. J Thorac Cardiovasc Surg. 2009; 138(2):446-53. DOI: 10.1016/j.jtcvs.2008.12.037. View

12.

Travis W . Advances in neuroendocrine lung tumors. Ann Oncol. 2010; 21 Suppl 7:vii65-71. DOI: 10.1093/annonc/mdq380. View

13.

Garassino M, Gelibter A, Grossi F, Chiari R, Soto Parra H, Cascinu S . Italian Nivolumab Expanded Access Program in Nonsquamous Non-Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients. J Thorac Oncol. 2018; 13(8):1146-1155. DOI: 10.1016/j.jtho.2018.04.025. View

14.

Kim H, Lee J, Jeong Nam S, Ock C, Moon J, Yoo C . Association of PD-L1 Expression with Tumor-Infiltrating Immune Cells and Mutation Burden in High-Grade Neuroendocrine Carcinoma of the Lung. J Thorac Oncol. 2018; 13(5):636-648. DOI: 10.1016/j.jtho.2018.01.008. View

15.

Sherman S, Rotem O, Shochat T, Zer A, Moore A, Dudnik E . Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC). Lung Cancer. 2020; 143:40-46. DOI: 10.1016/j.lungcan.2020.03.008. View

16.

Kupeli M, Koseoglu R . Large Cell Carcinoma with Adenocarcinoma in Lung. J Coll Physicians Surg Pak. 2018; 28(3):240-242. DOI: 10.29271/jcpsp.2018.03.240. View

17.

Weber M, Fottner C . Immune Checkpoint Inhibitors in the Treatment of Patients with Neuroendocrine Neoplasia. Oncol Res Treat. 2018; 41(5):306-312. DOI: 10.1159/000488996. View

18.

Sarkaria I, Iyoda A, Roh M, Sica G, Kuk D, Sima C . Neoadjuvant and adjuvant chemotherapy in resected pulmonary large cell neuroendocrine carcinomas: a single institution experience. Ann Thorac Surg. 2011; 92(4):1180-6. DOI: 10.1016/j.athoracsur.2011.05.027. View

19.

Komiya T, Ravindra N, Powell E . Role of Immunotherapy in Stage IV Large Cell Neuroendocrine Carcinoma of the Lung. Asian Pac J Cancer Prev. 2021; 22(2):365-370. PMC: 8190341. DOI: 10.31557/APJCP.2021.22.2.365. View

20.

Asamura H, Kameya T, Matsuno Y, Noguchi M, Tada H, Ishikawa Y . Neuroendocrine neoplasms of the lung: a prognostic spectrum. J Clin Oncol. 2005; 24(1):70-6. DOI: 10.1200/JCO.2005.04.1202. View